Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. (not Altimmune, Inc.) on December 7, 2011, reporting events occurring on December 1, 2011. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to equity compensation:
- Total Options Granted: 322,378 shares of common stock.
- Exercise Price: $1.21 per share (closing price on NYSE Amex on December 1, 2011).
- Option Term: 10 years.
- Recipients: Three executive officers, including Executive Vice President and Chief Scientific Officer Thomas R. Fuerst, Ph.D.
Material Changes
The material change reported is the grant of non-qualified stock options under the Company's 2007 Long-Term Incentive Compensation Plan. No changes to financial performance or operational status are reported in this document.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. The vesting schedule for the granted options is as follows:
- 225,000 shares: Vest 25% annually over four years beginning on the first anniversary of the grant date.
- 97,378 shares: Vest 100% on the first anniversary of the grant date.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., not Altimmune, Inc.
- Confirm the total number of options granted (322,378) and the specific allocation to Dr. Thomas R. Fuerst (104,545 total).
- Review the 2007 Long-Term Incentive Compensation Plan for details on dilution impact.
- Check subsequent filings for the actual vesting dates and exercise activity.